Barclays analyst Peter Lawson maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and maintains the target price at $60.
According to TipRanks data, the analyst has a success rate of 42.4% and a total average return of 1.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
Following the presentation of initial Phase 1 findings for RMC-9805 in advanced pancreatic ductal adenocarcinoma patients at the EORTC-NCI-AACR Symposium, an analyst noted increased optimism regarding the prospects of success for RMC-6036 in the current Phase 3 study for second-line PDAC, based on the recent update of Phase 1/1b data.
The analyst expressed satisfaction with Revolution Medicines' clinical updates on '6236 and '9805 in PDAC, which were discussed at a recent conference and investor event. The improvement seen in the updated '6236 Phase 1 data, particularly the first reported median overall survival data, bolsters the potential of '6236 to change the treatment landscape for second-line and beyond pancreatic ductal adenocarcinoma (PDAC). Additionally, the initial human data for '9805 in PDAC offers promising signs of clinical activity and a safety profile that exceeds initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Peter Lawson維持$Revolution Medicines (RVMD.US)$買入評級，維持目標價60美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.4%，總平均回報率為1.6%。
此外，綜合報道，$Revolution Medicines (RVMD.US)$近期主要分析師觀點如下：
在EORTC-NCI-AACR研討會上公佈了晚期胰腺導管腺癌患者中 RMC-9805 的初步1期研究結果後，一位分析師指出，根據最近更新的 10/10期數據，在目前的二線PDAC三期研究中，RMC-6036 的成功前景越來越樂觀。
這位分析師對Revolution Medicines關於PDAC中'6236和'9805的臨床更新表示滿意，最近的一次會議和投資者活動對此進行了討論。更新後的'6236第一階段數據，尤其是第一份報告的總存活率中位數數據所顯示的改善，增強了'6236改變二線及其他胰腺導管腺癌（PDAC）治療格局的潛力。此外，PDAC中'9805的初始人體數據提供了令人鼓舞的臨床活動跡象和超出最初預期的安全性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
